Onconetix Inc (ONCO) - Total Assets
Based on the latest financial reports, Onconetix Inc (ONCO) holds total assets worth $14.83 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Onconetix Inc (ONCO) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Onconetix Inc - Total Assets Trend (2019–2025)
This chart illustrates how Onconetix Inc's total assets have evolved over time, based on quarterly financial data. See Onconetix Inc net assets for net asset value and shareholders' equity analysis.
Onconetix Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Onconetix Inc's total assets of $14.83 Million consist of 24.3% current assets and 75.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.9% |
| Accounts Receivable | $296.87K | 1.2% |
| Inventory | $149.96K | 0.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $18.55 Million | 74.4% |
Asset Composition Trend (2019–2025)
This chart illustrates how Onconetix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Onconetix Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Onconetix Inc's current assets represent 24.3% of total assets in 2025, a decrease from 99.6% in 2019.
- Cash Position: Cash and equivalents constituted 20.9% of total assets in 2025, down from 99.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 74.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 74.4% of total assets.
Onconetix Inc Competitors by Total Assets
Key competitors of Onconetix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Onconetix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 0.17 | 3.86 |
| Quick Ratio | 1.37 | 0.16 | 3.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.26 Million | $-11.62 Million | $2.27 Million |
Onconetix Inc - Advanced Valuation Insights
This section examines the relationship between Onconetix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.10 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -11.5% |
| Total Assets | $24.93 Million |
| Market Capitalization | $947.78K USD |
Valuation Analysis
Below Book Valuation: The market values Onconetix Inc's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Onconetix Inc's assets decreased by 11.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Onconetix Inc (2019–2025)
The table below shows the annual total assets of Onconetix Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $24.93 Million | -11.55% |
| 2024-12-31 | $28.18 Million | -67.80% |
| 2023-12-31 | $87.52 Million | +232.64% |
| 2022-12-31 | $26.31 Million | +752.93% |
| 2021-12-31 | $3.08 Million | -35.90% |
| 2020-12-31 | $4.81 Million | -20.87% |
| 2019-12-31 | $6.08 Million | -- |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other … Read more